| NCT07164846 | Effect of Neuro20 Functional Electrical Stimulation Suit on Autonomic Function, Muscle Performance, and Gait | Brooks Rehabilitation | | - Age ≥ 18 yrs
- Level C1-S5
AIS - All
- NOT have implanted medical devices, a pacemaker, or defibrillator
- NOT have an implanted stimulator or pump that cannot be turned off externally
| Recruiting | 30 | NA | Rehabilitation | Standing/walking/mobility | - 6-Minute Walk Test (6MWT)
- Blood Pressure and Heart Rate Regulation
| 4 weeks | 05 August 2025 | 10 September 2025 | 2 | |
| NCT07234903 | ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury | Ecole Polytechnique Fédérale de Lausanne | | - Age 18 - 65 yrs
- Level C1-T10
AIS A, B, C, D- All
- NOT have any active implanted devices
| Recruiting soon | 12 | NA | Technology | General health | - 10 Meter Walking Test (10 MWT)
- 6-Minute Walk Test (6MWT)
- Adverse Events (AEs)
- American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
- Berg Balance Scale (BBS)
- Goal Attainment Scaling (GAS) score
- Spinal Cord Injury Functional Ambulation Inventory (SCI-FAI)
- Timed Up and Go Test (TUG)
- Walking Index for Spinal Cord Injury (WISCI) and WISCI II
| 6 years | 01 January 2026 | 19 November 2025 | 2 | |
| NCT07227285 | Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy | EG 427 | | - Age 18 - 75 yrs
- Level C1-L5
AIS A, B, C, D, E- ≥ 1 years
- have received at least one dose/injection of EG110A in Study EG110A-001-01 (NCT06596291: https://www.scitrialsfinder.net/trials/NCT06596291)
| Recruiting soon | 16 | PHASE1, PHASE2 | Drug | General health | | 5 years | 01 April 2026 | 12 November 2025 | 4 | |
| NCT07254767 | Virtual Walking and Neuromulation to Reduce Neuropathic Pain After a Spinal Cord Injury | Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal | | - Age ≥ 18 yrs
- Level C1-S5
AIS A, B, C, D- All
- NOT have a pacemaker or metallic implants in the brain or eyes
| Recruiting soon | 10 | NA | Technology | Pain | - Feasibility
- Numeric Pain Rating Scale
| 8 months | 01 December 2025 | 28 November 2025 | 0 | |
| NCT07223710 | Improving Walking After Spinal Cord Injury | Shirley Ryan AbilityLab | | - Age 18 - 75 yrs
- Level C1-T10
AIS C, D- ≥ 6 months
- NOT have metal implants in the head
| Recruiting soon | 20 | PHASE1, PHASE2 | Technology | Standing/walking/mobility | - 10 Meter Walking Test (10 MWT)
- Ashworth and Modified Ashworth Scale (MAS)
- Motor Evoked Potentials (MEPs)
| 12 days | 15 November 2025 | 03 November 2025 | 1 | |
| NCT07253233 | Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors | Third Affiliated Hospital, Sun Yat-Sen University | | - Age 18 - 60 yrs
- Level C1-S5
AIS C, D- All
| Recruiting soon | 10 | EARLY_PHASE1 | Drug | General health | - 10 Meter Walking Test (10 MWT)
- American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
- Ashworth and Modified Ashworth Scale (MAS)
- Hospital Anxiety and Depression Scale (HADS)
- Magnetic Resonance Imaging (MRI) - conventional/anatomical and quantitative
- Neurogenic Bowel Dysfunction Score (NBD or NBDS)
- Penn Spasm Frequency Scale (PSFS)
- Sensory evoked potentials (including mixed and dermatomal, mSSEPs, dSSEPs, contact heat/laser evoked potentials- CHEPS/LEPs)
- Spinal Cord Independence Measure (SCIM)
| 12 months | 01 December 2025 | 28 November 2025 | 0 | |
